Team:USTC CHINA

From 2013.igem.org

(Difference between revisions)
Line 46: Line 46:
                     </ul>
                     </ul>
               </li>
               </li>
-
                 <li><a href="https://2013.igem.org/Team:USTC_CHINA/team" target="_blank">Team</a>
+
                 <li><a href="https://2013.igem.org/Team:USTC_CHINA/team2" target="_blank">Team</a>
                 <ul class="subs">
                 <ul class="subs">
-
                         <li><a href="https://2013.igem.org/Team:USTC_CHINA/team" target="_blank">Members</a></li>
+
                         <li><a href="https://2013.igem.org/Team:USTC_CHINA/team2" target="_blank">Members</a></li>
                         <li><a href="https://igem.org/Team.cgi?year=2013&team_name=USTC_CHINA" target="_blank">Profile</a></li>
                         <li><a href="https://igem.org/Team.cgi?year=2013&team_name=USTC_CHINA" target="_blank">Profile</a></li>
                         <li><a href="https://2013.igem.org/Team:USTC_CHINA/Team/Attribute" target="_blank">Attribute</a></li>
                         <li><a href="https://2013.igem.org/Team:USTC_CHINA/Team/Attribute" target="_blank">Attribute</a></li>

Revision as of 15:58, 22 September 2013

USTC_China

In Situ Transdermal Vaccine

Fresh Expression, No Purification
Standardization, Block-based design
Easy-transportation, Low Storage External Costs
Almost No Demand For Medical Conditions And Proferssionals

Project Details

Why We Begin

we hope to provide a needle-free and non-skin-damage vaccination,
we hope everyone, even in the least developed area, could enjoy the benefit of medical progress.
more about project background

How We Design

With the support of TD-1, a special polypeptide, which can greatly facilitate macromolecule transdermal delivery through intact skin, we construct three different fuctional engineered bacillus subtilis; besides, we design a kill switch in the fouth type B.subtilis to ensure biosafety.
ANTIGEN
As the core of our in-situ system,
TD1-antigen expresser is designed
and will share a great percentage of
the total bacteria in our "band-aid".
more about project design
LTB
As one kind of our adjuvant expresser,
TD1-LTB is used to enhance the antigenicity.
For LTB has so many advantages, it's a wild using adjuvant for most of exsiting injected vaccine.
more about project design
KNFα
It's worth mentioning that to improve the effects of
traditional vaccine, as another kind of our TD1-adjuvant expresser, KNFα bear the weight of our hope to increase the sensitivity of our immune system.
more about project design
REPORTER
Reporter, which notifies users whether the status of vaccine patch is all right and when they can stick the patches to arms . Further more killing switch is existed in them as a biosafety guard.
more about project design

What We've Achived

Molecules part
We took E.coli and the PET vector as the positive control and realized our ideas in the B.subtilis expression system based on PHT43 shuttle vector.
more about project results
Protein part
Before we achieve fresh expression, we need first use purified protein to obtain exact data to verify our assumption.
more about project results
Mice experiments
The most obvious character of our 2013USTC iGEM team is that we have not only achieved a series of molecule experiments but also tried mice experiments, which could be divided into transdermal experiments in vitro and animate mice experiments
more about project results

Retrieved from "http://2013.igem.org/Team:USTC_CHINA"